Skip to main content



FOxTROT 3: A phase III randomized trial evaluating neoadjuvant chemotherapy with mFOLFOXIRI compared with neoadjuvant OxFp in patients with locally advanced but operable colon cancer
Status: Open

The standard treatment for bowel cancer has been to have surgery to remove the tumour, usually followed by chemotherapy. However, FOxTROT 1 research showed that giving chemotherapy before surgery was safe and reduced the chance of the cancer coming back. This means that giving chemotherapy before surgery (neoadjuvant chemotherapy) is now a standard treatment option for some bowel cancer patients.

Upon joining FOxTROT 3, patients will be randomly allocated either to receive the FOxTROT 3 approach – 6 weeks of ‘intensified’ neoadjuvant chemotherapy with three chemotherapy medicines) before surgery or ‘non-intensified’ neoadjuvant chemotherapy (two chemotherapy medicines) before surgery. Both sets of patients will also receive chemotherapy after surgery.

UK Hospitals Taking Part in the Trials

Below is a map of the UK hospitals taking part in the trials.

You can join here Opening soon

FOxTROT 3 Patient Information Sheet

For more detail on what the research might involve for you, please read the FOxTROT 3 Patient Information Sheet or speak to the team treating you.